Cargando…
Add-On Therapy with Traditional Chinese Medicine Improves Outcomes and Reduces Adverse Events in Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials
BACKGROUND AND AIMS: Traditional Chinese medicine (TCM) therapy for hepatocellular carcinoma remains controversial. This study aimed to evaluate the efficacy and safety of TCM regimens in HCC treatment. METHODS: Randomized controlled trials (RCTs) up to June 1, 2016, of the TCM treatment for hepatoc...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478821/ https://www.ncbi.nlm.nih.gov/pubmed/28680448 http://dx.doi.org/10.1155/2017/3428253 |
_version_ | 1783245031777239040 |
---|---|
author | Yang, Zongguo Liao, Xian Lu, Yunfei Xu, Qingnian Tang, Bozong Chen, Xiaorong Yu, Yongchun |
author_facet | Yang, Zongguo Liao, Xian Lu, Yunfei Xu, Qingnian Tang, Bozong Chen, Xiaorong Yu, Yongchun |
author_sort | Yang, Zongguo |
collection | PubMed |
description | BACKGROUND AND AIMS: Traditional Chinese medicine (TCM) therapy for hepatocellular carcinoma remains controversial. This study aimed to evaluate the efficacy and safety of TCM regimens in HCC treatment. METHODS: Randomized controlled trials (RCTs) up to June 1, 2016, of the TCM treatment for hepatocellular carcinoma were systematically identified in PubMed, CNKI, Ovid, Embase, Web of Science, Wanfang, VIP, CBM, AMED, and Cochrane Library databases. RESULTS: A total of 1010 and 931 patients in 20 RCTs were randomly treated with add-on TCM therapy and conventional therapy, respectively. The additional use of TCM significantly improved six-month, one-year, two-year, and three-year overall survival rates in HCC cases (RR = 1.3, P = 0.01; RR = 1.38, P = 0.0008; RR = 1.44, P < 0.0001; RR = 1.31, P = 0.02, resp.). Add-on TCM therapy significantly increased PR rate and total response rate (tRR) and reduced PD rate compared to those in control group (34.4% versus 26.3%, RR = 1.30, P = 0.002; 41.6% versus 31.0%, RR = 1.30, P < 0.0001; and 16.6% versus 26.5%, RR = 0.64, P < 0.0001, resp.). Additionally, TCM combination therapy significantly increased the quality of life (QOL) improvement rate and reduced adverse events including leukopenia, thrombocytopenia, anemia or erythropenia, liver injury, and gastrointestinal discomfort in HCC patients (all P < 0.05). CONCLUSION: Add-on therapy with TCM could improve overall survival, increase clinical tumor responses, lead to better QOL, and reduce adverse events in hepatocellular carcinoma. |
format | Online Article Text |
id | pubmed-5478821 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-54788212017-07-05 Add-On Therapy with Traditional Chinese Medicine Improves Outcomes and Reduces Adverse Events in Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials Yang, Zongguo Liao, Xian Lu, Yunfei Xu, Qingnian Tang, Bozong Chen, Xiaorong Yu, Yongchun Evid Based Complement Alternat Med Review Article BACKGROUND AND AIMS: Traditional Chinese medicine (TCM) therapy for hepatocellular carcinoma remains controversial. This study aimed to evaluate the efficacy and safety of TCM regimens in HCC treatment. METHODS: Randomized controlled trials (RCTs) up to June 1, 2016, of the TCM treatment for hepatocellular carcinoma were systematically identified in PubMed, CNKI, Ovid, Embase, Web of Science, Wanfang, VIP, CBM, AMED, and Cochrane Library databases. RESULTS: A total of 1010 and 931 patients in 20 RCTs were randomly treated with add-on TCM therapy and conventional therapy, respectively. The additional use of TCM significantly improved six-month, one-year, two-year, and three-year overall survival rates in HCC cases (RR = 1.3, P = 0.01; RR = 1.38, P = 0.0008; RR = 1.44, P < 0.0001; RR = 1.31, P = 0.02, resp.). Add-on TCM therapy significantly increased PR rate and total response rate (tRR) and reduced PD rate compared to those in control group (34.4% versus 26.3%, RR = 1.30, P = 0.002; 41.6% versus 31.0%, RR = 1.30, P < 0.0001; and 16.6% versus 26.5%, RR = 0.64, P < 0.0001, resp.). Additionally, TCM combination therapy significantly increased the quality of life (QOL) improvement rate and reduced adverse events including leukopenia, thrombocytopenia, anemia or erythropenia, liver injury, and gastrointestinal discomfort in HCC patients (all P < 0.05). CONCLUSION: Add-on therapy with TCM could improve overall survival, increase clinical tumor responses, lead to better QOL, and reduce adverse events in hepatocellular carcinoma. Hindawi 2017 2017-06-07 /pmc/articles/PMC5478821/ /pubmed/28680448 http://dx.doi.org/10.1155/2017/3428253 Text en Copyright © 2017 Zongguo Yang et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Yang, Zongguo Liao, Xian Lu, Yunfei Xu, Qingnian Tang, Bozong Chen, Xiaorong Yu, Yongchun Add-On Therapy with Traditional Chinese Medicine Improves Outcomes and Reduces Adverse Events in Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials |
title | Add-On Therapy with Traditional Chinese Medicine Improves Outcomes and Reduces Adverse Events in Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials |
title_full | Add-On Therapy with Traditional Chinese Medicine Improves Outcomes and Reduces Adverse Events in Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials |
title_fullStr | Add-On Therapy with Traditional Chinese Medicine Improves Outcomes and Reduces Adverse Events in Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials |
title_full_unstemmed | Add-On Therapy with Traditional Chinese Medicine Improves Outcomes and Reduces Adverse Events in Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials |
title_short | Add-On Therapy with Traditional Chinese Medicine Improves Outcomes and Reduces Adverse Events in Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials |
title_sort | add-on therapy with traditional chinese medicine improves outcomes and reduces adverse events in hepatocellular carcinoma: a meta-analysis of randomized controlled trials |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478821/ https://www.ncbi.nlm.nih.gov/pubmed/28680448 http://dx.doi.org/10.1155/2017/3428253 |
work_keys_str_mv | AT yangzongguo addontherapywithtraditionalchinesemedicineimprovesoutcomesandreducesadverseeventsinhepatocellularcarcinomaametaanalysisofrandomizedcontrolledtrials AT liaoxian addontherapywithtraditionalchinesemedicineimprovesoutcomesandreducesadverseeventsinhepatocellularcarcinomaametaanalysisofrandomizedcontrolledtrials AT luyunfei addontherapywithtraditionalchinesemedicineimprovesoutcomesandreducesadverseeventsinhepatocellularcarcinomaametaanalysisofrandomizedcontrolledtrials AT xuqingnian addontherapywithtraditionalchinesemedicineimprovesoutcomesandreducesadverseeventsinhepatocellularcarcinomaametaanalysisofrandomizedcontrolledtrials AT tangbozong addontherapywithtraditionalchinesemedicineimprovesoutcomesandreducesadverseeventsinhepatocellularcarcinomaametaanalysisofrandomizedcontrolledtrials AT chenxiaorong addontherapywithtraditionalchinesemedicineimprovesoutcomesandreducesadverseeventsinhepatocellularcarcinomaametaanalysisofrandomizedcontrolledtrials AT yuyongchun addontherapywithtraditionalchinesemedicineimprovesoutcomesandreducesadverseeventsinhepatocellularcarcinomaametaanalysisofrandomizedcontrolledtrials |